AAV214D5

**AAV214D5** appears to be an experimental engineered adeno-associated virus capsid rather than a clearly identified standalone therapeutic drug product. Publicly available Abeona Therapeutics disclosures describe AAV214D5 alongside AAV214 as proprietary capsids that, in non-human primate retinal studies, showed transduction of photoreceptor and retinal pigment epithelium cells at levels similar to AAV8, suggesting intended use as a **gene therapy delivery vector** for inherited retinal diseases. However, no specific transgene payload, finished product name, clinical-stage candidate designation, route, dosage form, or disease-specific program tied uniquely to AAV214D5 could be confirmed from the available public sources.